Abbvie Inc's Corporate Customers have recorded an advance in their cost of revenue by 8.42 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -5.98 %. During the corresponding time, Abbvie Inc recorded a revenue increase by 12.43 % year on year, sequentially revenue fell by -9.72 %. While revenue at the Abbvie Inc 's corporate clients recorded rose by 5.5 % year on year, sequentially revenue fell by -2.35 %.
Abbvie Inc's Customers have recorded an advance in their cost of revenue by 8.42 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -5.98 %, for the same period Abbvie Inc recorded revenue increase by 12.43 % year on year, sequentially revenue fell by -9.72 %.
Abbvie Inc's Comment on Sales, Marketing and Customers
AbbVie markets its products globally to wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies, independent retailers, physicians, and other licensed healthcare providers. In the United States, AbbVie primarily distributes pharmaceutical products through independent wholesale distributors, with McKesson Corporation, Cardinal Health, Inc., and Cencora, Inc. accounting for the majority of pharmaceutical product sales in 2025. Outside the United States, AbbVie sells mainly to wholesalers or through distributors and collaborates with centralized national payer systems for reimbursement. The company also markets directly to consumers in the U.S., although many products require prescriptions. AbbVie offers patient support programs related to its products. The company operates in highly competitive markets, facing competition from other research-based pharmaceutical and biotechnology companies offering immunology products such as IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, and biosimilars; oncology products including BTK inhibitors, ADCs, and cell therapies; as well as products competing with Botox. Competition arises from new product introductions, changes in medical practices, price competition, and substitution by generic and biosimilar products.
In a pivotal moment for both Cerevel Therapeutics Holdings, Inc. and AbbVie Inc. a cloud of uncertainty has descended upon investors as they grapple with a growing class action lawsuit and escalating operational costs affecting corporate clients. As legal proceedings loom, the financial landscape reveals mixed signals that warrant a detailed examination.Levi and Korsinsky, LLP has officially notified investors in Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV) about a pending class action securities lawsuit, emphasizing the lead plaintiff deadline of June 3, 2025. The potential implications of this lawsuit could significantly impact investor sentiment and set the stage for an unpredictable future for the co...
COPENHAGEN, Denmark - New pivotal data introduced an innovative beacon of hope for patients dealing with hard-to-treat follicular lymphoma (FL). Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced promising results from their ongoing phase 1/2 EPCORE NHL-1 clinical trial investigation, focusing on the bispecific antibody epcoritamab (DuoBody CD3xCD20). Administered subcutaneously, epcoritamab demonstrated an overall response rate (ORR) of 82 percent and a complete response (CR) rate of 63 percent. Pleasingly, minimal residual disease (MRD) negativity rate was observed at 67 percent in patients with relapsed or refractory Follicular Lymphoma. Contrastingly, AbbVie Inc. has been navigating ro...
Abbvie Inc’s Comment on Sales, Marketing and Customers
AbbVie markets its products globally to wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies, independent retailers, physicians, and other licensed healthcare providers. In the United States, AbbVie primarily distributes pharmaceutical products through independent wholesale distributors, with McKesson Corporation, Cardinal Health, Inc., and Cencora, Inc. accounting for the majority of pharmaceutical product sales in 2025. Outside the United States, AbbVie sells mainly to wholesalers or through distributors and collaborates with centralized national payer systems for reimbursement. The company also markets directly to consumers in the U.S., although many products require prescriptions. AbbVie offers patient support programs related to its products. The company operates in highly competitive markets, facing competition from other research-based pharmaceutical and biotechnology companies offering immunology products such as IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, and biosimilars; oncology products including BTK inhibitors, ADCs, and cell therapies; as well as products competing with Botox. Competition arises from new product introductions, changes in medical practices, price competition, and substitution by generic and biosimilar products.
Sources:
Abbvie Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Abbvie Inc’s corporate clients.
For your research, we’ve provided 9 tables on Abbvie Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
6.83 %
5.52 % 